ATOMIC Trial – PD-L1 pulse FOLFOX as adjuvant in CRC

The ATOMIC trial evaluated the efficacy of combining the PD-L1 inhibitor atezolizumab with standard adjuvant chemotherapy (FOLFOX) in patients with stage III colon cancer that is mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-high). Below is a detailed breakdown of the trial and its findings:

---

Key Details of the ATOMIC Trial

Study Design

• Population: 712 patients with stage III colon cancer that is dMMR/MSI-high.
• Intervention Groups:
• Control arm: FOLFOX alone for 6 months.
• Experimental arm: FOLFOX + atezolizumab for 6 months, followed by atezolizumab alone for an additional 6 months.
• Primary Endpoint: Disease-Free Survival (DFS) — the time patients remain free of cancer recurrence or progression.

---

Results

• DFS Rates:
• Patients receiving atezolizumab + FOLFOX had a DFS of 86.4%.
• Patients receiving FOLFOX alone had a DFS of 76.6%.
• Conclusion: The addition of atezolizumab to FOLFOX significantly improved DFS, demonstrating a strong survival benefit for the immunotherapy combination.
• Hazard Ratio (HR): The trial showed a robust HR favoring the combination therapy, indicating reduced risk of recurrence or progression with atezolizumab.

---

Implications

1. Potential New Standard of Care:

• The findings suggest that atezolizumab + FOLFOX could become the new adjuvant standard for patients with stage III dMMR/MSI-high colon cancer.
• This is particularly relevant because dMMR/MSI-high colon cancer represents a subset (~10%) of all colon cancers.

2. Practice-Changing Potential:

• The trial highlights the importance of immune checkpoint inhibitors like atezolizumab in the adjuvant setting for colon cancer patients with dMMR/MSI-high tumors, a group that is highly responsive to immunotherapy due to their immunogenic nature.

---

Remaining Questions

While the ATOMIC trial provides compelling evidence for the combination therapy, several questions remain unanswered:

1. Duration of Chemotherapy:

• Is 6 months of FOLFOX necessary, or could 3 months (as increasingly common in practice) suffice?
• Shorter chemotherapy durations might reduce toxicity without compromising efficacy.

2. Role of Atezolizumab Alone:

• Could atezolizumab alone (without FOLFOX) be just as effective for these patients, given the strong immunogenicity of dMMR/MSI-high tumors?

3. Optimal Duration of Atezolizumab:

• Should atezolizumab be administered for 6 months, 12 months, or even 24 months? Longer durations might improve outcomes but raise concerns about toxicity and cost.

4. Toxicity and Cost:

• What are the long-term side effects and financial implications of adding atezolizumab to standard chemotherapy?

---

Significance

Although only ~10% of colon cancers are dMMR/MSI-high, this trial has the potential to change clinical practice for this subgroup. The combination of immunotherapy with chemotherapy represents a promising strategy to improve outcomes in patients with this specific molecular profile.